Sheila R Botts

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Margaret Ackman Michele Arthur Kelly Babcock Jana Bajcar Ray Bisson Anne-Marie Bombassaro Sheila Botts Michel Boucher Susan Bowles Jean-François Bussières Roxanne Carr Doret Cheng Tom Chin Elaine Chong Judy Chong Céline Corman Sherry Coutts Dawn Dalen Natalie Dayneka Ron Donnelly Anar Dossa Maj DE (Doug) Doucette Susan Fagan Susan Fryters Laurence Galanti(More)
Over the past decade, a new class of atypical antipsychotic drugs has been developed for the treatment of schizophrenia and related conditions. This new generation of antipsychotic agents represents the first significant breakthrough in the treatment of schizophrenia since the advent of chlorpromazine in the early 1950s. Although the designation "atypical"(More)
MetabolicMonitoring in Commercially Insured Pediatric Patients Newly Initiated to Take a Second-Generation Antipsychotic The use of second-generation antipsychotics (SGAs) in children and adolescents has increased amidst the concern for adverse effects (AEs) on overall health. The use of SGAs increases the risk for weight gain, elevated glucose, insulin(More)
PURPOSE The development, implementation, and scaling of 3 population-based specialty care programs in a large integrated healthcare system are reviewed, and the role of clinical pharmacy services in ensuring safe, effective, and affordable care is highlighted. SUMMARY The Kaiser Permanente (KP) integrated healthcare delivery model allows for rapid(More)
  • 1